MARKSANS PHARMA LIMITED (MARKSANS) financials

MARKSANS PHARMA LIMITED (MARKSANS) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products[1]

Market Cap: ₹14,338Cr.
Current Price: ₹316
Stock P/E: 44.6
ROE: 19.7%
ROCE: 25.6%
Book Value: ₹36.5
Dividend Yield: 0.28%
52W High / Low: ₹351/155

In Jun 2026, MARKSANS PHARMA LIMITED (MARKSANS) reported sales ₹321 Cr and net profit ₹69 Cr.

Annual TTM: sales ₹1,343 Cr, net profit ₹322 Cr.

Shareholding: Promoters 43.87% (Jun 2026), FIIs 17.47% (Jun 2026), DIIs 6.19% (Jun 2026), Public 32.46% (Jun 2026), No. of Shareholders 2,46,635% (Jun 2026).

MARKSANS quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	309	312	299	320	320	340	362	321
Expenses	245	252	248	250	248	264	256	239
Operating Profit	63	60	52	70	72	75	106	82
OPM %	21%	19%	17%	22%	22%	22%	29%	26%
Other Income	20	23	7	2	58	16	27	17
Interest	0	0	0	0	0	0	0	0
Depreciation	7	7	8	8	8	9	9	9
Profit before tax	76	75	50	64	121	82	124	90
Tax %	17%	26%	25%	24%	18%	26%	26%	24%
Net Profit	63	55	38	48	100	61	92	69
EPS in Rs	1.39	1.22	0.83	1.06	2.20	1.34	2.03	1.52
Raw PDF	—	—	—	—	—	—	—	—

MARKSANS profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	433	600	658	655	853	1,174	1,341	1,343
Expenses	362	486	545	563	713	966	1,018	1,007
Operating Profit	71	114	114	92	140	208	324	336
OPM %	16%	19%	17%	14%	16%	18%	24%	25%
Other Income	0	31	42	60	62	66	103	119
Interest	7	5	4	4	1	1	1	1
Depreciation	12	15	18	17	29	29	34	35
Profit before tax	53	124	135	132	172	243	392	418
Tax %	28%	21%	23%	22%	22%	23%	23%	—
Net Profit	38	98	104	103	134	188	301	322
EPS in Rs	0.93	2.40	2.54	2.27	2.95	4.15	6.64	7.09
Dividend Payout %	11%	10%	10%	22%	20%	19%	14%	—

MARKSANS balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	41	41	41	41	45	45	45	45
Reserves	430	465	559	744	1,066	1,177	1,338	1,607
Borrowings	78	11	14	14	8	8	11	12
Other Liabilities	64	83	127	167	226	285	361	330
Total Liabilities	612	600	741	966	1,345	1,516	1,755	1,994
Fixed Assets	103	115	129	136	144	272	383	398
CWIP	0	0	0	0	4	0	0	0
Investments	236	236	236	237	266	293	266	267
Other Assets	273	249	375	594	931	952	1,105	1,329
Total Assets	612	600	741	966	1,345	1,516	1,755	1,994

MARKSANS cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	20	108	107	56	52	34	31	211
Cash from Investing Activity	-20	-24	9	-128	-195	-114	17	-141
Cash from Financing Activity	1	-82	-14	71	210	-26	-30	-39
Net Cash Flow	1	2	102	-1	67	-106	18	31
Free Cash Flow	-4	83	86	33	16	-121	-89	163
CFO/OP	52%	165%	112%	77%	91%	52%	37%	88%

MARKSANS shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%
FIIs	21.31%	21.95%	22.19%	19.89%	16.92%	8.13%	16.76%	17.47%
DIIs	4.10%	4.30%	4.55%	5.50%	5.28%	5.91%	6.57%	6.19%
Public	30.70%	29.88%	29.37%	30.74%	33.93%	42.08%	32.78%	32.46%
No. of Shareholders	2,48,845	2,59,813	2,57,273	2,56,221	2,65,788	2,55,153	2,46,279	2,46,635

MARKSANS key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	153	136	103	137	170	158	171	170
Inventory Days	109	111	101	100	121	145	117	102
Days Payable	58	84	69	72	103	122	116	97
Cash Conversion Cycle	204	163	135	165	188	182	172	174
Working Capital Days	127	144	90	110	143	144	145	150
ROCE %	12%	11%	23%	20%	14%	15%	19%	26%

MARKSANSUpdated 13 Oct 2026, 5:46

Marksans Pharma Limited

MARKSANSUpdated 13 Oct 2026, 5:46

Market Cap

₹14,338Cr.

Current Price

₹316

High / Low

₹351/155

Stock P/E

44.6

ROE19.7%

ROCE25.6%

Book Value₹36.5

Face Value₹1.00

Dividend Yield0.28%

About

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	182	155	33	5	54	19	44	0.98
Sep 2023	205	167	16	8	44	30	31	0.69
Dec 2023	241	199	1	8	35	27	25	0.56
Mar 2024	225	191	12	7	38	14	33	0.73
Jun 2024	255	213	8	7	42	24	32	0.71
Sep 2024	309	245	20	7	76	17	63	1.39
Dec 2024	312	252	23	7	75	26	55	1.22
Mar 2025	299	248	7	8	50	25	38	0.83
Jun 2025	320	250	2	8	64	24	48	1.06
Sep 2025	320	248	58	8	121	18	100	2.2
Dec 2025	340	264	16	9	82	26	61	1.34
Mar 2026	362	256	27	9	124	26	92	2.03
Jun 2026	321	239	17	9	90	24	69	1.52

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	406	13	290	3	9	97	31	67	1.64
Mar 2016	358	6	254	9	15	92	22	71	1.75
Mar 2017	216	4	191	7	15	12	3	12	0.28
Mar 2018	295	8	266	7	12	17	25	12	0.3
Mar 2019	424	7	361	8	9	56	22	44	1.07
Mar 2020	433	7	362	0	12	53	28	38	0.93
Mar 2021	600	5	486	31	15	124	21	98	2.4
Mar 2022	658	4	545	42	18	135	23	104	2.54
Mar 2023	655	4	563	60	17	132	22	103	2.27
Mar 2024	853	1	713	62	29	172	22	134	2.95
Mar 2025	1174	1	966	66	29	243	23	188	4.15
Mar 2026	1341	1	1018	103	34	392	23	301	6.64
TTM	1343	1	1007	119	35	418	—	322	7.09

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	43.87%
FIIs	17.47%
DIIs	6.19%
Public	32.46%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	43.85%	15.07%	4.02%	37.06%
Dec 2023	43.85%	15.55%	4.76%	35.81%
Mar 2024	43.85%	15.57%	5.17%	35.4%
Jun 2024	43.87%	18.59%	3.75%	33.77%
Sep 2024	43.87%	21.31%	4.1%	30.7%
Dec 2024	43.87%	21.95%	4.3%	29.88%
Mar 2025	43.87%	22.19%	4.55%	29.37%
Jun 2025	43.87%	19.89%	5.5%	30.74%
Sep 2025	43.87%	16.92%	5.28%	33.93%
Dec 2025	43.87%	8.13%	5.91%	42.08%
Mar 2026	43.87%	16.76%	6.57%	32.78%
Jun 2026	43.87%	17.47%	6.19%	32.46%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	41	305	62	119	527	90	0	68	369	527
Mar 2016	41	369	53	71	534	97	0	231	205	534
Mar 2017	41	378	73	54	546	94	0	234	217	546
Mar 2018	41	388	67	61	557	88	0	236	233	557
Mar 2019	41	430	78	64	612	103	0	236	273	612
Mar 2020	41	465	11	83	600	115	0	236	249	600
Mar 2021	41	559	14	127	741	129	0	236	375	741
Mar 2022	41	744	14	167	966	136	0	237	594	966
Mar 2023	45	1066	8	226	1345	144	4	266	931	1345
Mar 2024	45	1177	8	285	1516	272	0	293	952	1516
Mar 2025	45	1338	11	361	1755	383	0	266	1105	1755
Mar 2026	45	1607	12	330	1994	398	0	267	1329	1994

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	112	-29	51	134
Mar 2016	65	-177	-52	-164
Mar 2017	-14	-8	21	-1
Mar 2018	16	-8	-10	-2
Mar 2019	20	-20	1	1
Mar 2020	108	-24	-82	2
Mar 2021	107	9	-14	102
Mar 2022	56	-128	71	-1
Mar 2023	52	-195	210	67
Mar 2024	34	-114	-26	-106
Mar 2025	31	17	-30	18
Mar 2026	211	-141	-39	31

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	112	136	262	209	153	136	103	137	170	158	171	170
Inventory Days	85	90	95	91	109	111	101	100	121	145	117	102
Days Payable	75	64	67	73	58	84	69	72	103	122	116	97
Cash Conversion Cycle	123	161	290	228	204	163	135	165	188	182	172	174
Working Capital Days	29	91	177	149	127	144	90	110	143	144	145	150
ROCE %	33%	22%	3%	5%	12%	11%	23%	20%	14%	15%	19%	26%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of MARKSANS PHARMA LIMITED (MARKSANS)?

The reported market capitalisation for MARKSANS PHARMA LIMITED (MARKSANS) is ₹14,338Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of MARKSANS?

The current price shown for MARKSANS PHARMA LIMITED (MARKSANS) on Fincrux is ₹316 with a 52-week high/low of ₹351/155.

What is the P/E ratio of MARKSANS PHARMA LIMITED (MARKSANS)?

The stock P/E for MARKSANS PHARMA LIMITED (MARKSANS) is 44.6 on Fincrux, with ROE at 19.7% and ROCE at 25.6%.

What were MARKSANS latest quarterly results?

For Jun 2026, MARKSANS PHARMA LIMITED (MARKSANS) reported sales ₹321 Cr and net profit ₹69 Cr (figures in ₹ crore unless noted).

What are MARKSANS annual sales and net profit?

For TTM, MARKSANS PHARMA LIMITED (MARKSANS) shows sales of ₹1,343 Cr and net profit of ₹322 Cr on the Fincrux profit & loss statement.

Who owns MARKSANS PHARMA LIMITED (MARKSANS)?

Latest shareholding for MARKSANS PHARMA LIMITED (MARKSANS) on Fincrux: Promoters 43.87% (Jun 2026), FIIs 17.47% (Jun 2026), DIIs 6.19% (Jun 2026), Public 32.46% (Jun 2026), No. of Shareholders 2,46,635% (Jun 2026).

Where can I find MARKSANS PHARMA LIMITED (MARKSANS) financials?

MARKSANS PHARMA LIMITED (MARKSANS) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show MARKSANS balance sheet and cash flow?

Yes. The MARKSANS PHARMA LIMITED (MARKSANS) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 13 October 2026 at 5:46